Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects
It plays a crucial role in brain function and the production of DNA and red blood cells
A powerful combination of peptides stacked together: BPC-157, TB-500, GHK-Cu, and KPV, work synergistically to help you heal, repair, and recover faster
Blood sugar control and metabolic benefits Both CagriSema and tirzepatide produce substantial improvements in glycemic markers, but the mechanisms driving these improvements differ, and the magnitude varies between populations
May 1, 2025
Promote angiogenesis the growth of new blood vessels, improving nutrient delivery to damaged tissue, particularly helpful with wounds
US$ 24.05
US$ 21.84
US$ 25.95
US$ 28.62
